PositiveID Corporation Files Patent for Glucose-Sensing System
25-Aug-2011
|
Source :
|
Visits : 10031
DELRAY BEACH, Fla. - PositiveID Corporation, a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced in a press release that it has filed a patent with the US Patent and Trademark Office (USPTO) for its recently completed stable and reproducible, closed-cycle continuous glucose-sensing system that is the mission-critical component of its GlucoChip™ glucose-sensing microchip for patients with diabetes. PositiveID now has five patents and patents pending surrounding the development of GlucoChip.
Last week, the Company, in conjunction with its development partner RECEPTORS LLC ("Receptors"), announced it had completed Phase II of the GlucoChip development program, with the creation and demonstration of a continuous glucose-sensing system that consistently functions in the human blood fractions that are relevant to glucose analysis in the human body. PositiveID and Receptors published results from their laboratory testing in a white paper titled, "Development of the Sensing System for an Implantable Glucose Sensor," available at http://www.positiveidcorp.com/files/ImplantableGlucoseSensorWhitePaper.pdf.
PositiveID has also filed a patent application with the USPTO covering a passive radio frequency ("RF") powered electromechanical sensor for the continuous detection of glucose levels in a patient. This new system integrates RF technology, such as that described in PositiveID's previously issued Patent No. 7,125,382 entitled "Embedded Bio-Sensor System." This patent and patent application utilize RF identification technology and include a remote transponder in wireless communication with an implantable passively-powered on-chip transponder. One or more micro-electromechanical system (MEMS) devices inside the sensor register physical changes reflecting glucose levels in vivo, which are communicated via integrated electronics to an external reader.
Robert E. Carlson, president and chief scientific officer of Receptors, said, "We continue to make considerable progress in the development of GlucoChip. The filing of this latest patent covering the glucose-sensing system represents our successful development of the core component of GlucoChip™, the stable, synthetic chemistry that responds to changing levels of glucose. We are now in an excellent position to initiate integration of the biocompatibility, MEMS signal transduction and RFID communication components into the GlucoChip prototype."
GlucoChip is based on the Company's FDA cleared microchip for patient identification, the VeriChip, and the Company's Embedded Bio-Sensor System patent. The Company's Embedded Bio-Sensor System patent covers a bio-sensor system that utilizes radio frequency identification technology and includes a remote transponder in wireless communication with an implantable passively-powered on-chip transponder. PositiveID also has an exclusive license, for use in the GlucoChip application, to Receptors' Patent No. 7,504,364 titled "Methods of Making Arrays and Artificial Receptors" and Patent No. 7,469,076 "Sensors Employing Combinatorial Artificial Receptors."
Receptors LLC develops Smart Materials products for laboratory, clinical, industrial hygiene and healthcare use that selectively capture and measure chemical, biochemical and cellular targets from complex biological, environmental or industrial samples.